Sapheon hauls in $10M as it works toward FDA approval for a varicose vein device

North Carolina's Sapheon pulled down $10 million in financing to support the development of its VenaSeal system, a varicose vein-treating device going through the FDA's modular approval program. Under the agency's guidance, Sapheon has submitted the second round of data on VenaSeal and is in the midst of a 242-patient pivotal trial with hopes of getting the device approved by 2015. More

Suggested Articles

They say you are what you eat, but scientists at Rice University and the University of Washington may be taking that maxim a step further.

Acutus secured $170 million after acquiring a catheter developer and announcing a slew of new partnerships in arrhythmia treatment and monitoring.

Tangen Biosciences, developers of cheap and portable molecular diagnostics for outside the lab, has raised $9 million to kick off its VC efforts.